Navigation Links
SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
Date:9/16/2008

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical devices company, today announced that it is shipping its WavSTAT(R) Optical Biopsy System to the Mayo Clinic and to the University of California San Diego/VA to complete a study at each site. The purpose of this study is to demonstrate the clinical value of the Optical Biopsy System as an adjunctive tool to improve an endoscopists' clinical sensitivity in identifying dysplasia or cancer in the esophagus. This will be the final phase of the study which has been conducted over the past three years.

The WavSTAT Optical Biopsy System was approved by the FDA in November of 2000 as safe and effective for adjunctive use during endoscopy of the colon to improve the endoscopist's clinical sensitivity to identify pre-cancerous polyps. The system received the CE Mark in Europe in September 2007. The approved WavSTAT System uses a low power, non-significant risk laser to scan tissue and instantaneously help the physician determine whether small polyps are normal or pre-cancerous without physically removing the tissue. If they are pre-cancerous, they are removed during the same procedure.

Current standards of care dictate that if a patient has severe chronic symptoms of heartburn, an endoscopy of the esophagus may be warranted and if indicated, multiple physical biopsies are taken to check for pathology such as Barrett's esophagus, dysplasia or cancer. During endoscopic examination, the diseased tissue is not always visually apparent, especially at the pre- malignant stages. Therefore, the endoscopist physically biopsies visually suspicious areas within and outside the Barrett's area, areas with nodules or generally suspicious locations. The endoscopist also takes multiple representative samples by physical biopsy in an effort to find diseased tissue.

The clinical use of the WavSTAT System to improve the endoscopist's clinical sensi
'/>"/>

SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. SpectraScience Awarded Patent for Correcting Image Misalignment
8. Laser Energetics Delivers BrightStar(TM) Alexandrite Laser to Fortune 50 Defense Company
9. Lilly Delivers Strong Third-Quarter Results
10. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
11. E.D.G.E. in Leadership Study Delivers First-Ever Data on Executive Women in Pharmaceutical and Biotech Industries
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:CVS Joins Retail Push for Non-Toxic Personal Care Products 2Health News:CVS Joins Retail Push for Non-Toxic Personal Care Products 3Health News:The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008 2Health News:AIDS.gov Goes 2.0: Government HIV/AIDS Website Now Features a Blog, Podcasts, and More 2Health News:Hunger Hormone Makes Food Look More Tasty 2Health News:Hunger Hormone Makes Food Look More Tasty 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 4Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 5Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 6Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 7Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 2Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 3Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 4Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 5
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 1Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 1Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 3Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 4
Other Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8